TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27872863

Group type: EXPERIMENTAL
Intervention: cetirizine + methylphenidate
Number of subjects: 38

Group type: COMPARATOR
Intervention: cetirizine
Number of subjects: 38

Group type: COMPARATOR
Intervention: sustained-release methylphenidate
Number of subjects: 38
Study: 24136652

Group type: EXPERIMENTAL
Intervention: Explosive-type moderate-resistance training (EMRT) for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explosive-type moderate-resistance training (EMRT)
Number of subjects: 0
Study: 22531559

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) with Sighs (30 cm H2O peak airway pressure, administered once per minute)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) with Sighs
Number of subjects: 20
Study: 20491708

Group type: EXPERIMENTAL
Intervention: Positioning strategies
Number of subjects: 126

Group type: COMPARATOR
Intervention: Positioning plus Safe T Sleep™ positioning wrap
Number of subjects: 126
Study: 18829790

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum and Lactobacillus acidophilus added to breast milk or mixed feeding, twice daily for 6 weeks
Number of subjects: 434

Group type: COMPARATOR
Intervention: Breast milk or mixed feeding (control group)
Number of subjects: 434
Study: 15549624

Group type: EXPERIMENTAL
Intervention: Transcutaneous absorbable sutures (4-0 polyglactin 910)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subcuticular absorbable sutures (4-0 polyglactin 910)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adhesive papertape
Number of subjects: 60
Study: 12425849

Group type: EXPERIMENTAL
Intervention: Inhalation of 50% nitrous oxide and oxygen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inhalation of air and oxygen (Control)
Number of subjects: 30
Study: 10347295

Group type: EXPERIMENTAL
Intervention: Endoscopic Sclerotherapy (EIS), n = 55
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Endoscopic Ligation (EVL), n = 52
Number of subjects: 157

Group type: COMPARATOR
Intervention: Nontreated Control Group, n = 50
Number of subjects: 157
Study: 8538445

Group type: EXPERIMENTAL
Intervention: Verbalization and instructions to search for the rules in the simple task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbalization and instructions to search for the rules in the complex task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational-learning condition in the simple task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational-learning condition in the complex task
Number of subjects: 0
Study: 1956211

Group type: EXPERIMENTAL
Intervention: Nifedipine (40 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31227872

Group type: COMPARATOR
Intervention: ARID5B SNPs (rs10821936, rs10994982, rs7089424, rs2393732, rs2393782, rs2893881, rs4948488)
Number of subjects: 298

Group type: COMPARATOR
Intervention: CAG haplotype (rs10821936, rs10994982, rs7089424)
Number of subjects: 298

Group type: COMPARATOR
Intervention: G allele at rs2893881
Number of subjects: 298
Study: 29308593

Group type: EXPERIMENTAL
Intervention: ADF IR formulation of an opioid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Marketed IR formulation
Number of subjects: 24
Study: 24777621

Group type: EXPERIMENTAL
Intervention: Probiotic food supplement (Lactobacillus rhamnosus R0011 1.9×10^9 cfu and L. acidophilus R0052 0.1×10^9 cfu/d for 7 days)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard therapy (oral rehydration solution and zinc)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Probiotic food supplement
Number of subjects: 112
Study: 23586657

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg administered three times per day for 48 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo administered three times per day for 48 hours
Number of subjects: 30
Study: 21473840

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) before laser preparation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-LLT (without low level laser therapy) before laser preparation
Number of subjects: 10
Study: 19770393

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 10 microg/kg, n=26
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo, n=26
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 17324738

Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg (n = 18)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lisinopril (after 14 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (after 14 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15155205

Group type: EXPERIMENTAL
Intervention: Atazanavir (300 mg) and Ritonavir (100 mg) QD + Tenofovir DF QD (from day 15)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Atazanavir (300 mg) and Ritonavir (100 mg) QD
Number of subjects: 11
Study: 11495174

Group type: EXPERIMENTAL
Intervention: DRT plus life-skills training
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DRT plus booster sessions
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DRT plus life-skills training and booster sessions
Number of subjects: 144

Group type: COMPARATOR
Intervention: DRT only
Number of subjects: 144
Study: 9710007

Group type: EXPERIMENTAL
Intervention: Dominant T-cell clones in patients with idiopathic sensory neuropathies
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dominant T-cell clones in chronic idiopathic axonal polyneuropathy (CIAP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dominant T-cell clones in chronic idiopathic ataxic neuropathy (CIAN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Elderly normal controls
Number of subjects: 20

Group type: COMPARATOR
Intervention: Elderly controls with degenerative neurologic diseases
Number of subjects: 20

Group type: COMPARATOR
Intervention: Elderly patients with idiopathic chronic inflammatory demyelinating polyneuropathy
Number of subjects: 20
Study: 7991905

Group type: EXPERIMENTAL
Intervention: Propofol (1.5‐2.5 mg/kg for induction; 6‐12 mg/kg continuous infusion for maintenance)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neuroleptanalgesia (sodium thiopental 4‐5 mg/kg for induction; droperidol 0.15 microgram/kg/h and 50% N2O/O2 for maintenance)
Number of subjects: 30
Study: 2903110

Group type: EXPERIMENTAL
Intervention: Pentasa (5-aminosalicylic acid) 1500 mg t.i.d. (three times a day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Salazopyrin (sulfasalazine) 3 g t.i.d.
Number of subjects: 75
Study: 31366394

Group type: EXPERIMENTAL
Intervention: bCPAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 0
Study: 28745686

Group type: EXPERIMENTAL
Intervention: LPD (0.6 g of protein per kg of body weight/day) with keto/amino acid ketosteril (1 tablet per 5 kg of body weight/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LPD (0.6 g of protein per kg of body weight/day) with keto/amino acid ketoaminol (1 tablet per 5 kg of body weight/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: LPD without keto/amino acids (control group)
Number of subjects: 90
Study: 26182929

Group type: EXPERIMENTAL
Intervention: Anti-fatigue mat
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal rigid surface
Number of subjects: 16
Study: 24120216

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) 600 mg once-daily
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) 400 mg once-daily
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 168
Study: 21994958

Group type: EXPERIMENTAL
Intervention: PTH(1-84)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 97
Study: 18268174

Group type: COMPARATOR
Intervention: Control group (follow-up by a cardiologist)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Basic support group (nurse support)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Intensive support group (nurse support)
Number of subjects: 1023
Study: 17154666

Group type: EXPERIMENTAL
Intervention: Combination therapy with beta-lactam plus macrolide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monotherapy with respiratory fluoroquinolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-lactam monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-lactam alone at adequate dosage
Number of subjects: 0
Study: 14555558

Group type: EXPERIMENTAL
Intervention: Ilo‐Neb/Aerotrap nebulizer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ventstream nebulizer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HaloLite nebulizer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All nebulizers (Ilo‐Neb/Aerotrap, Ventstream, HaloLite)
Number of subjects: 12
Study: 11012656

Group type: EXPERIMENTAL
Intervention: 0.5% bupivicaine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Saline (dummy injection)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No injection
Number of subjects: 92
Study: 9120111

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam and Propofol
Number of subjects: 40
Study: 1428132

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT‐MTX) with cranial radiotherapy (RT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Intrathecal methotrexate (IT‐MTX) alone
Number of subjects: 76
Study: 3917884

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.9% NaCl solution (saline) infusion
Number of subjects: 10
Study: 31301739

Group type: EXPERIMENTAL
Intervention: Physiotherapist assessment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Physician assessment
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both assessments (physiotherapist and physician)
Number of subjects: 69
Study: 28865067

Group type: EXPERIMENTAL
Intervention: CPAP treatment in sleep unit (SU) setting
Number of subjects: 191

Group type: COMPARATOR
Intervention: CPAP treatment in primary care (PC) setting
Number of subjects: 191
Study: 26257209

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM) training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 24666929

Group type: EXPERIMENTAL
Intervention: Music intervention (30 minutes of Turkish art music during hemodialysis sessions, 12 total sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 60
Study: 22186709

Group type: EXPERIMENTAL
Intervention: Mindfulness-based group intervention (Vitality Training Programme - VTP)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (routine care plus a CD for voluntary use with mindfulness-based home exercises)
Number of subjects: 73
Study: 20102888

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (low-dose bisoprolol regimen started ≥30 days before surgery)
Number of subjects: 3884

Group type: COMPARATOR
Intervention: No beta-blocker therapy (control group)
Number of subjects: 3884

Group type: EXPERIMENTAL
Intervention: History of stroke
Number of subjects: 3884

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 3884

Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 3884

Group type: EXPERIMENTAL
Intervention: Bisoprolol therapy
Number of subjects: 3884
Study: 17469694

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idazoxan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium plus fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium plus paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1‐deprenyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium EDTA
Number of subjects: 0
Study: 16036038

Group type: EXPERIMENTAL
Intervention: Management of atrial fibrillation post-myocardial infarction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrinolysis treatment
Number of subjects: 0
Study: 12073958

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG), measured 4 times daily using a reflectance meter with memory
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group with periodic monitoring at prenatal visits
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 58
Study: 9796636

Group type: EXPERIMENTAL
Intervention: PXM 10 mg every other day (q.o.d.)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: DFMO 0.5 g/m2
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PXM 10 mg q.o.d.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: DFMO/PXM combination
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PXM alone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: DFMO/PXM
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PXM/DFMO
Number of subjects: 43
Study: 7662205

Group type: EXPERIMENTAL
Intervention: Recently diagnosed HIV-positive men (within 2-4 months)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Asymptomatic men
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Symptomatic men
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Men diagnosed less recently
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Interpersonal reactions of those informed
Number of subjects: 684
Study: 2748112

Group type: EXPERIMENTAL
Intervention: Cataract surgery alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combined surgery (cataract surgery with posterior lip sclerectomy or trabeculectomy)
Number of subjects: 68
Study: 702248

Group type: EXPERIMENTAL
Intervention: Transported by a trained physician and nurse
Number of subjects: 0
Study: 30985930

Group type: EXPERIMENTAL
Intervention: Work-related medical rehabilitation (intervention group)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Conventional medical rehabilitation (control group)
Number of subjects: 484
Study: 27933424

Group type: EXPERIMENTAL
Intervention: New Beginnings Program (NBP)
Number of subjects: 477
Study: 26825640

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24477618

Group type: EXPERIMENTAL
Intervention: Combination of α‐lipoic acid (ALA) 600 mg and superoxide dismutase (SOD) 140 IU daily with physiotherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 96
Study: 23257368

Group type: EXPERIMENTAL
Intervention: Self-expanding stent (STENTYS, STENTYS SA, Paris, France)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Balloon-expandable stent (VISION, Abbott Vascular, Santa Clara, California; or Driver, Medtronic, Minneapolis, Minnesota)
Number of subjects: 80
Study: 20622702

Group type: EXPERIMENTAL
Intervention: Focus Progressives
Number of subjects: 20

Group type: COMPARATOR
Intervention: PureVision Multifocal
Number of subjects: 20
Study: 17955550

Group type: EXPERIMENTAL
Intervention: Long interval regimen (dornase alfa nebulization with >6 hr dwell time)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Short interval regimen (dornase alfa nebulization with ≤6 hr dwell time)
Number of subjects: 20
Study: 15992517

Group type: EXPERIMENTAL
Intervention: Esterified plant stanols (2 to 3 g/day) incorporated in margarines or spreads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esterified plant stanols in low-fat food products
Number of subjects: 0
Study: 12815797

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (LP) at 7 mmHg
Number of subjects: 82
Study: 10102975

Group type: EXPERIMENTAL
Intervention: 75 mg ranitidine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 mg famotidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7568481

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg
Number of subjects: 859

Group type: COMPARATOR
Intervention: Midazolam 0.1 mg/kg plus ketamine 0.4 to 0.5 mg/kg
Number of subjects: 859
Study: 2174783

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) s.c. every 12 h, initial dose about 100 U/kg bodyweight
Number of subjects: 71

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 71
Study: 7305609

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31154309

Group type: EXPERIMENTAL
Intervention: 4-week intervention comprising the provision of free plant-based meat alternatives, written information on health and environmental benefits, success stories, and recipes.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention control condition.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-week intervention.
Number of subjects: 0
Study: 28882655

Group type: EXPERIMENTAL
Intervention: Brief in-hospital psychological intervention (two 1 h 15 min sessions and a 20-minute follow-up session)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (standard medical care without psychological intervention)
Number of subjects: 121
Study: 25273982

Group type: EXPERIMENTAL
Intervention: Bladder training (scheduled clamping and unclamping of the trans-urethral catheter every three hours)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control (no bladder training)
Number of subjects: 111
Study: 25084625

Group type: EXPERIMENTAL
Intervention: Coaching intervention (The Academy for Future Science Faculty) including annual in-person meetings and ongoing virtual coaching.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 22179079

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.25 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (400 μg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35
Study: 20960541

Group type: EXPERIMENTAL
Intervention: Immediate PCI (≤6 hours) with double bolus of eptifibatide
Number of subjects: 54

Group type: COMPARATOR
Intervention: Early PCI (7‐72 hours) with upstream eptifibatide
Number of subjects: 54
Study: 17693888

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vCP1452 alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vCP1452 plus MN rgp120
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 15709843

Group type: EXPERIMENTAL
Intervention: Teacher-administered cognitive-behavioral intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitoring-control condition
Number of subjects: 0
Study: 15177064

Group type: EXPERIMENTAL
Intervention: Entacapone 200mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10784384

Group type: COMPARATOR
Intervention: Antioxidant supplement (beta-carotene, lycopene, lutein, canthaxanthin, alpha-tocopherol) without dietary fiber
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement with pectin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement with guar
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement with cellulose
Number of subjects: 6
Study: 7597693

Group type: EXPERIMENTAL
Intervention: Therapeutic electrical stimulation (TES) applied to the affected muscles in the right upper and lower extremities for more than 3 months.
Number of subjects: 1

Group type: COMPARATOR
Intervention: Non-treated side (left side) without TES intervention.
Number of subjects: 1
Study: 2192771

Group type: EXPERIMENTAL
Intervention: Selenium-ACE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6989687

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 100 mg slow-release tablets (morning or evening dose)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg enteric-coated tablets b.i.d.
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 30908338

Group type: EXPERIMENTAL
Intervention: Test lens with 0.019 mg ketotifen
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control lens with no added drug
Number of subjects: 244
Study: 28294499

Group type: EXPERIMENTAL
Intervention: Dulaglutide/glargine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo/glargine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 300
Study: 25757954

Group type: EXPERIMENTAL
Intervention: Treadmill training with visual biofeedback
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treadmill training without visual biofeedback
Number of subjects: 50
Study: 23570863

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 800 mg QD for 15 days with OC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg QD for 15 days with OC
Number of subjects: 20

Group type: COMPARATOR
Intervention: OC alone (30 μg ethinylestradiol and 150 μg levonorgestrel)
Number of subjects: 20
Study: 20972537

Group type: EXPERIMENTAL
Intervention: Web-based PISQ-12
Number of subjects: 52

Group type: COMPARATOR
Intervention: Paper-based PISQ-12
Number of subjects: 52
Study: 19906341

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (fixed doses: 50, 100, 200, or 400 mg/d; flexible doses: 100-400 mg/d)
Number of subjects: 2913

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2913